Phase 2 N=30 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
Sarcoma
Primary: Proportion of Patients Who Achieve a Clinical Response — 0.33 proportion
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)
Hypophosphatasia (HPP)
Primary: Change in Rickets Severity on Skeletal Radiographs From Baseline to Week 24 as Measured by the Radiographic Global Impression of Change (RGI-C) Scale — 0; 2.00 units on…
Phase 2 N=35 Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Brain and Central Nervous System Tumors
Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months
Phase 2 N=109 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
Phase 2 N=12 Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation
Wounds
Primary: Time to Complete Wound Closure (Epithelialization) — 15; 15 days
Phase 2 N=117 A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy
Hepatitis C
Primary: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Treatment — 60.5; 52.9; 100.0…
Phase 2 N=26 Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation
Wounds
Primary: Time to Complete Wound Closure (Epithelialization) — 10.9; 13.1; 16.3 days — p=0.0062
Phase 2 N=22 Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Carcinoma of the Head and Neck
Primary: Completion Rate — 100 percentage of participants
Phase 2 N=83 Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
Breast Neoplasms
Primary: Number of Participants With Objective Response — 7 Participants
Phase 2 N=12 Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease
Blood Platelet Disorders
Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants
Phase 2 N=323 Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
Chronic Hepatitis C
Primary: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing — 46.3; 69.1; 59.8…
Phase 2 N=453 A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
Hepatitis C
Primary: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing — 51.3; 53.1; 24.3…
Phase 2 N=250 Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
Chronic Hepatitis C
Primary: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing — 41.3; 67.1; 60.8…
Phase 2 N=149 Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus Type 2
Primary: Changes in Fasting Plasma Glucose (FPG) From Baseline at Week 4 for Segment 2 of the Study — -12.595; -29.518; -30.429; -32.586 mg/dL — p=0.0989
Phase 2 N=26 Treating Nonalcoholic Steatohepatitis (NASH) With Metformin
Hepatitis
Primary: Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category) — 9; 11; 5; 1 participants — p=<0.001